Excalibur Fund Managers

Neurotech is a privately held biotechnology company developing sight-saving therapeutics for chronic retinal diseases–including indications with significant unmet medical need that, as a whole, represent the largest market opportunity in ophthalmology.

Takeda Cambridge Limited (TCB) and its subsidiary TSP, have established world-class target identification and validation capabilities. Together they have developed a promising pipeline of novel drug discovery targets and compounds in key areas of unmet medical need such as CNS disorders, chronic pain and urology indications, endocrinology and metabolic-related diseases.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.

Intercytex Group plc, a development stage biotechnology company, engages in the research, development, and commercialization of cell-based therapies for the repair and regeneration of skin and hair. The company, using its integrated cell technology platform, develops living, human cell-based products. Its product programs in development include VAVELTA, a facial rejuvenation and skin damage repair product, which completed Phase II trials; SHEF-1-Stem Cell Line, which would develop a cure for AMD, the leading cause of blindness in the elderly; ICX-TRC, a hair regeneration product that completed Phase II trials; and ICX-SKN, a skin graft replacement for burns and acute wounds, which completed Phase I trial. The company was founded in 2000 and is headquartered in Cambridge, the United Kingdom.

Takeda Cambridge Limited (TCB) and its subsidiary TSP, have established world-class target identification and validation capabilities. Together they have developed a promising pipeline of novel drug discovery targets and compounds in key areas of unmet medical need such as CNS disorders, chronic pain and urology indications, endocrinology and metabolic-related diseases.

Destination Skin is a skin and laser hair removal clinics in London.

Plethora Solutions (AIM: PLE) is a specialty pharmaceutical company dedicated to the development and marketing of products for the treatment and management of urological disorders. The diagnosis and treatment of urological conditions represent an expanding market with many poorly met medical needs that offer the significant commercial potential for new pharmaceutical products and medical devices. The Company's principal product is a treatment remedy for male premature ejaculation which obtained marketing authorization from the European Commission on 19 November 2013. Although the European MAA has been authorized by the European Commission, the information contained on this website is provided for business development and investor relations purposes only. Patients who suffer or believe they suffer from PE should contact their physician in the first instance.

Neurotech is a privately held biotechnology company developing sight-saving therapeutics for chronic retinal diseases–including indications with significant unmet medical need that, as a whole, represent the largest market opportunity in ophthalmology.

Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annual funding of £3.8 million.

Piramed Limited, a biotech company, discovers and develops new medicines for the treatment of cancer and immune inflammatory disorders. The company focuses on the discovery and development of inhibitors to find clinical utility in various diseases, including cancer, immune inflammatory disorders, cardiovascular disease, and pain, as well as metabolic and infectious diseases. The company was incorporated in 2001 and is based in Slough, the United Kingdom. As of May 23, 2008, Piramed Limited operates as a subsidiary of Hoffmann-La Roche Inc.

Energist designs, manufactures, markets, and supplies lasers and light-based systems for hair removal and aesthetic skin treatments in medical and beauty sectors. It offers variable and intense pulsed light systems for hair removal and aesthetic skin rejuvenation treatments. Energist also provides laser systems, including light emitting diode (LED) and CO2 lasers for medical and surgical applications. Moreover, it offers LED systems and micro-needle rollers for anti-ageing treatment applications. Energist’s products are also used for aesthetic and surgical applications, such as vascular and skin rejuvenation, resurfacing, and regeneration. It sells its products directly, as well as through distributors worldwide. Energist began operation in 1999, with its headquarters in Swansea in the United Kingdom. Energist operates as a subsidiary of Energist Medical Group.

Arakis Limited is focuses on discovery and development of inflammatory diseases and oncology adjunctive therapy. The company's research capability specializes in the cytokine and receptor mediated mechanisms of disease. The company identifies, develops, and commercializes product opportunities based upon new clinical uses for known drugs or known drug templates, as well as termed performance enhanced medicines.

Microscience is a biotechnology company focussed on the discovery and development of innovative rationally designed vaccines for the prophylaxis and treatment of disease in areas of significant unmet clinical need. Microscience, which was founded in 1997, has used proprietary functional genomics and vaccine technology expertise as the basis of an expanding product portfolio. The Company’s secure intellectual property – with three granted patents and many others covering over 300 genes and targets – underpins the product development, providing long-term intellectual property protection well beyond the projected product launch dates.

Ardana Bioscience was created in July 2000 to commercialise research by the Medical Research Council (MRC )'s Human Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland which has been at the forefront of this area of research for the last 28 years. The MRC employs nearly 100 staff at the Unit which currently receives total annual funding of £3.8 million.

EpiCept Corporation headquarters are located in Englewood Cliffs, New Jersey, with a subsidiary company, EpiCept GmbH in Munich Germany. This transatlantic presence facilitates access to European technology and markets and enhances financing and liquidity opportunities. EpiCept and its subsidiary are focused on developing novel, effective, safe and economical prescription pain products delivering drugs to a target area by using a topical delivery approach as opposed to systemic or transdermal modes. It is envisioned that EpiCept products will have significant market potential. The products are protected by an aggressive patent program.

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.

TME Pharma is a biopharmaceutical company, develops biostable aptamers and substances based on mirror image nucleic acids. Its Spiegelmer is a mirror image oligonucleotide therapeutic for the pharmacologically relevant target. The company has a strategic alliance with Pfizer, Inc. NOXXON Pharma AG was founded in 1997 and is based in Berlin, Germany.

Microscience is a biotechnology company focussed on the discovery and development of innovative rationally designed vaccines for the prophylaxis and treatment of disease in areas of significant unmet clinical need. Microscience, which was founded in 1997, has used proprietary functional genomics and vaccine technology expertise as the basis of an expanding product portfolio. The Company’s secure intellectual property – with three granted patents and many others covering over 300 genes and targets – underpins the product development, providing long-term intellectual property protection well beyond the projected product launch dates.

Arakis Limited is focuses on discovery and development of inflammatory diseases and oncology adjunctive therapy. The company's research capability specializes in the cytokine and receptor mediated mechanisms of disease. The company identifies, develops, and commercializes product opportunities based upon new clinical uses for known drugs or known drug templates, as well as termed performance enhanced medicines.

Microscience is a biotechnology company focussed on the discovery and development of innovative rationally designed vaccines for the prophylaxis and treatment of disease in areas of significant unmet clinical need. Microscience, which was founded in 1997, has used proprietary functional genomics and vaccine technology expertise as the basis of an expanding product portfolio. The Company’s secure intellectual property – with three granted patents and many others covering over 300 genes and targets – underpins the product development, providing long-term intellectual property protection well beyond the projected product launch dates.

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

Vectura Group is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases. This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth in excess of $30 billion worldwide.

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the Company in 1996. In 1999, Cyclacel Pharmaceuticals was joined by Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle.

ReNeuron Group engages in the research, development, and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications.